Journal: iScience

Article Title: Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection

doi: 10.1016/j.isci.2025.112617

Figure Lengend Snippet: Performance comparison between CA125 alone, ctDNA alone, and the combination test (A) Receiver operator characteristic (ROC) curves for CA125 alone, ctDNA alone, and the combination test using the validation dataset ( n = 127). (B) Comparison of sensitivity, specificity, and accuracy between the different biomarkers in the training, validation and the entire dataset. The cutoff value for CA125 was 35 U/mL; the cutoff values for the ctDNA and CA125+ctDNA models were defined using the Youden Index. (C) Venn diagram showing the number and proportion of patients with OC identified using the different biomarkers at 95% specificity in the validation and entire cohort. (D) Overall sensitivities for CA125 alone, ctDNA alone, and the combination test at 95% specificity in the validation and entire cohort. (E) Sensitivity of different biomarkers stratified by tumor stage at 95% specificity in the validation and entire cohort. (F) Sensitivity of different indicators stratified by tumor stage at 95% specificity in patients with epithelial OC and non-epithelial OC. (G) ROC curves for CA125 alone and CA125+ctDNA in the CancerSEEK external validation cohort. (H) Comparison of sensitivity, specificity, and accuracy between the two biomarkers in the external validation cohort. The black lines indicate the 95% confidence intervals for sensitivity. AUC: area under the curve; CI: confidence interval; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Groups with statistical differences are labeled.

Article Snippet: Moreover, the detection rate of early-stage OC (stage I and II) appeared to be higher in EOC groups than in non-EOC group for almost all the indicators; however, only CA125 showed a statistically significant difference (Chi-squared test, p = 0.03).

Techniques: Comparison, Biomarker Discovery, Labeling

Journal: iScience

Article Title: Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection

doi: 10.1016/j.isci.2025.112617

Figure Lengend Snippet: Performance comparison among the three combination tests (A) Receiver operator characteristic (ROC) curves for the ROMA, CA125+ctDNA, and EarlySEEK tests determined using the validation dataset. (B) Comparison of sensitivity, specificity, and accuracy between the ROMA model and the two combined biomarkers in different datasets. The cutoff values for the ROMA model in the premenopausal and postmenopausal populations were 11.4 and 29.9, respectively. The Youden Index was used to determine the threshold for the CA125+ctDNA and EarlySEEK and models. (C) Venn diagram showing the number and proportion of patients with OC identified based on the ROMA, CA125+ctDNA, and EarlySEEK tests at 95% and 98% specificity. (D) Overall sensitivities of the ROMA, CA125+ctDNA, and EarlySEEK combination tests at 95% and 98% specificity in the entire cohort. (E) Sensitivities of the ROMA, CA125+ctDNA, and EarlySEEK models stratified by tumor stage at 95% and 98% specificity. (F) Sensitivities of the ROMA, CA125+ctDNA, and EarlySEEK models at 95% and 98% specificity in different tumor types and at different tumor stages. (G) Identification of different indicators in patients with OC who tested negative for CA125 (<35 U/mL) at 95% specificity. The black lines indicate the 95% confidence intervals for sensitivity. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Groups with statistical differences are labeled.

Article Snippet: Moreover, the detection rate of early-stage OC (stage I and II) appeared to be higher in EOC groups than in non-EOC group for almost all the indicators; however, only CA125 showed a statistically significant difference (Chi-squared test, p = 0.03).

Techniques: Comparison, Biomarker Discovery, Labeling

Journal: Nature Communications

Article Title: Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

doi: 10.1038/s41467-025-59888-8

Figure Lengend Snippet: A Clustering UMAPs of tumor epithelial cells ( N = 8553) extracted from the main dataset color-coded by cluster and annotated according to tumor ID. Cluster 13 (ellipse) is annotated separately due to contributions from multiple tumors. B Cluster composition by patient/tumor. C Table displaying primary and secondary histologic patterns observed in each tumor and percentage of cells within Cluster 13. D Curated dot plot of top differentially expressed genes (DEGs) by tumor cluster. E Serial section immunohistochemistry of MUC4, CA125, and KRT24 in variant tumors ( N = 2 of 2 cases). F Representative immunohistochemistry of CA125 in multiple histologic variants. All scale bars = 50 µm. G Preoperative serum CA125 values in bladder cancer patients stratified by tumor grade and histology (Two-way Mann–Whitney U-test, p = 0.007). Quartiles, centers and outliers are shown in the box plot. Source data are provided as a Source data file.

Article Snippet: Serum CA125 levels were prospectively measured in patients undergoing TURBT or cystectomy for bladder tumors using the Abbott Architect Chemiluminescent Microparticle Immunoassay (CMIA) and reviewed under IRB 10-04057.

Techniques: Immunohistochemistry, Variant Assay, MANN-WHITNEY

Journal: Nature Communications

Article Title: Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

doi: 10.1038/s41467-025-59888-8

Figure Lengend Snippet: A Gene ontology analysis of Cluster 13 gene signature. B Representative CA125 immunohistochemistry in a primary HV bladder tumor and the corresponding lymph node metastasis ( N = 4 of 5 cases examined). C Intratumoral comparison of Cluster 13 and parent tumor gene signature susceptibility to common bladder cancer chemotherapeutic agents in 5 HV tumors. D Kaplan–Meier curves of overall and disease-specific survival according to Cluster 13 signature enrichment in TCGA-BLCA (log-rank test, p = 0.01 for overall survival; p = 0.03 for disease-specific survival). Data are presented as mean values ± standard error. Source data are provided as a Source data file.

Article Snippet: Serum CA125 levels were prospectively measured in patients undergoing TURBT or cystectomy for bladder tumors using the Abbott Architect Chemiluminescent Microparticle Immunoassay (CMIA) and reviewed under IRB 10-04057.

Techniques: Immunohistochemistry, Comparison